Immix Biopharma (NASDAQ:IMMX - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Monday,Zacks.com reports.
A number of other brokerages have also weighed in on IMMX. Wall Street Zen upgraded shares of Immix Biopharma to a "hold" rating in a report on Friday, June 27th. HC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Immix Biopharma in a report on Wednesday, June 4th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Immix Biopharma currently has an average rating of "Moderate Buy" and an average price target of $7.00.
View Our Latest Analysis on Immix Biopharma
Immix Biopharma Stock Up 1.0%
Shares of NASDAQ IMMX opened at $2.12 on Monday. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $3.20. The firm has a market cap of $61.12 million, a P/E ratio of -2.75 and a beta of 0.28. The company has a 50 day moving average of $2.50 and a 200 day moving average of $2.10.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.01). As a group, equities analysts expect that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Immix Biopharma
A number of large investors have recently added to or reduced their stakes in the stock. Velan Capital Investment Management LP bought a new stake in Immix Biopharma in the 2nd quarter worth approximately $52,000. Tritonpoint Wealth LLC bought a new stake in Immix Biopharma in the 2nd quarter worth approximately $51,000. Finally, Jane Street Group LLC bought a new stake in Immix Biopharma in the 4th quarter worth approximately $39,000. Institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access